The company is actively working to resolve issues at its Indore, India manufacturing facility under FDA scrutiny, which caused a negative financial impact in 2025.
Filing excerpt
Viatris made substantial progress on its initial remediation activities at its oral finished dose manufacturing facility in Indore, India, including but not limited to related personnel actions.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kregulatoryInvestigationGet every 10-K signal for Viatris and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/2b539028-4003-4fc1-a181-7b7436b1dad8 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.
{
"signal_id": "2b539028-4003-4fc1-a181-7b7436b1dad8",
"signal_type": "sec-10k",
"signal_subtype": "regulatoryInvestigation",
"detected_at": "2026-03-03T06:02:41.098+00:00",
"company": {
"name": "Viatris",
"domain": "viatris.com"
},
"data": {
"detail": "The company is actively working to resolve issues at its Indore, India manufacturing facility under FDA scrutiny, which caused a negative financial impact in 2025. This creates an urgent need for solutions in quality management systems (QMS), compliance tracking, and supply chain monitoring to satisfy FDA requirements and restore operations.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Viatris remediating Indore facility following FDA warning letter and import alert.",
"excerpts": "Viatris made substantial progress on its initial remediation activities at its oral finished dose manufacturing facility in Indore, India, including but not limited to related personnel actions.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm",
"filing_date": "2026-02-26",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Compliance tools urgently needed",
"signal_category": "risk",
"regions_mentioned": [
"India"
]
}
}
curl https://signals.autobound.ai/v1/signals/2b539028-4003-4fc1-a181-7b7436b1dad8 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.